Main menu


Israeli medicine Clearmind obtains US patent for

featured image

you.S. Extension of the Patent and Trademark Officeunder the protection of Clearmind owner MEAI and expands its potential market

Tel Aviv, Israel / Vancouver, Canada, Dec. Feb. 21, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotechnology company focused on the discovery and development of new psychedelic-derived therapies to solve major outsourced health problems, announced that it had been granted a patent by the United States Patent and Trademark Office (USPTO) for the use of its proprietary MEAI as alcoholic beverage substitute.

Similar patents have already been granted to Clearmind for the MEAI-based alcohol substitute in Europe and India.

US patent development No. 11 077 072 B2 – is a major milestone, given the growing popularity and growth in sales of non-alcoholic wines, beers and spirits. According to the information services company NielsenIQ, the market for these soft drinks in the United States in August 2022 was worth 395 million dollars per year, showing an annual growth of + 20.6%.

“This patent is great news as we continue to strengthen and expand protection around our innovative compounds, reflecting growing US recognition of our innovative portfolio,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “It’s a huge boost, because the United States is one of the biggest markets for alcohol substitutes.”

This positive momentum confirms the value of the innovative R&D approach that underpins our business strategy. This reinforces our prospects for a new large market, different from the pharmaceutical market and with the short-term potential of generating considerable revenues. Zuloff-Shani added.

The patent follows the appointment of former Red Bull Canada executive Nicholas Kadysh as special advisor on the regulatory development of MEAI as an alcohol substitute. Kadysh, who also worked at Juul Labs Canada, is a career expert on managing complex regulatory risks in the health and food industry. He is the founder of PharmAla Biotech, which manufactures MDMA and MDXX class molecules for pharmaceutical research, and the Chairman of the Board of Psychedelics Canada, the trade association of the Canadian for-profit psychedelics industry.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of novel psychedelic-derived therapies to address widespread and underserved health conditions, including alcohol use disorders. Its main focus is to research and develop psychedelic-based compounds and attempt to market them as regulated drugs, foods, or supplements.

The Company’s intellectual portfolio currently consists of seven patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind’s shares are listed on the Nasdaq under the symbol “CMND”, on the Canadian Securities Exchange under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY”.

For more information visit: or contact:

Investor Relations
Phone: (604) 260-1566
General Information


This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” and similar expressions or variations of these words are intended identify forward-looking statements. For example, the Company uses forward-looking statements when discussing its patent portfolio, business strategy and the Company’s outlook for an important new market, different from the pharmaceutical market and with near-term revenue generation potential. . Forward-looking statements are not historical facts and are based on management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be realized, and actual results may differ materially from what is expressed or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to , the risks detailed in the company’s Final Prospectus (registration number 333-265900) filed with the SEC on November 16, 2022. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting the forward-looking information, except to the extent required by applicable securities laws. If the Company updates one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and information contained on such websites is not incorporated by reference in this press release. Clearmind is not responsible for the content of third party websites.